Intas cuts Razumab supplies after adv...
Home  »  Community News  »  Intas cuts Razumab s...
Aug
21
ragupathyrenganathan
Intas cuts Razumab supplies after adverse eye reactions
Pharma News
0

MUMBAI: Indian pharmaceutical and biotechnology firm Intas Biopharmaceuticals has “curtailed the distribution” of Razumab, an injectable drug used for treating macular degeneration, barely two months after its launch following stray incidents of adverse reactions like inflammation in eyes.

Razumab, a biosimilar of Genentech’s Lucentis, was launched in June at about 25% cheaper than the innovator drug marketed by Novartis.

Two renowned eye care experts confirmed to ET that Raz ..



Leave a reply

You must be logged in to post a comment.